Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9724028rdf:typepubmed:Citationlld:pubmed
pubmed-article:9724028lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:9724028lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:9724028lifeskim:mentionsumls-concept:C0140079lld:lifeskim
pubmed-article:9724028lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:9724028lifeskim:mentionsumls-concept:C0011155lld:lifeskim
pubmed-article:9724028lifeskim:mentionsumls-concept:C1709694lld:lifeskim
pubmed-article:9724028pubmed:issue9lld:pubmed
pubmed-article:9724028pubmed:dateCreated1998-9-23lld:pubmed
pubmed-article:9724028pubmed:abstractTextTo investigate endoproteolytic processing of the type I insulin-like growth factor receptor (IGF-IR), we have examined its structure and activity in the furin-deficient LoVo-C5 cell line. Immunoprecipitation experiments using the monoclonal anti-IGF-IR antibody (alpha-IR3) showed that LoVo-C5 cells expressed a major high molecular mass receptor (200 kDa) corresponding to the unprocessed alpha/beta pro-receptor. A small amount of successfully cleaved alpha/beta heterodimers was also produced, indicating a residual endoproteolytic cleavage activity in these cells. In vitro, a soluble form of recombinant furin was able to cleave the pro-IGF-IR (200 kDa) into alpha-subunit (130 kDa) and beta-subunit (97 kDa). Measurement of IGF binding parameters in LoVo-C5 cells indicated a low number of typical type I IGF-binding sites (binding capacity, 5 x 10(3) sites/cell; Kd, 1.9 nM for IGF-I and 7.0 nM for IGF-II). These findings in LoVo-C5 contrast with those in HT29-D4 cells, which have active furin, and where IGF-IR (2.8 x 10(4) sites/cell) was fully processed. Moreover, the 200-kDa pro-IGF-IR of LoVo-C5 was unable to induce intracellular signaling, such as beta-subunit tyrosine autophosphorylation and insulin-related substrate-1 tyrosine phosphorylation. Flow immunocytometry analysis using alpha-IR3 antibody indicated that LoVo-C5 cells expressed 40% more receptors than HT29-D4 cells, suggesting that in LoVo-C5 cells only the small amount of mature type I IGF-IR binds IGFs with high affinity. To provide evidence for this idea, we showed that mild trypsin treatment of living LoVo-C5 cells partially restored alpha/beta cleavage of IGF-IR, and greatly enhanced (6-fold) the IGF-I binding capacity of LoVo-C5 cells, but did not restore IGF-IR signaling activity. Moreover, LoVo-C5 cells were totally unresponsive to IGF-I in terms of cell migration, in contrast to fully processed IGF-IR-HT29-D4 cells. Our data indicate that furin is involved in the endoproteolytic processing of the IGF-IR and suggest that this posttranslational event might be crucial for its ligand binding and signaling activities. However, our data do not exclude that other proprotein convertases could participate to IGF-IR maturation.lld:pubmed
pubmed-article:9724028pubmed:languageenglld:pubmed
pubmed-article:9724028pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9724028pubmed:statusMEDLINElld:pubmed
pubmed-article:9724028pubmed:monthSeplld:pubmed
pubmed-article:9724028pubmed:issn0013-7227lld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:LehmannMMlld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:AndräAAlld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:PommierGGlld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:Remacle-Bonne...lld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:MarvaldiJJlld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:LissitskyJ...lld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:GarrousteFFlld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:BellasFFlld:pubmed
pubmed-article:9724028pubmed:authorpubmed-author:ParabPPlld:pubmed
pubmed-article:9724028pubmed:issnTypePrintlld:pubmed
pubmed-article:9724028pubmed:volume139lld:pubmed
pubmed-article:9724028pubmed:ownerNLMlld:pubmed
pubmed-article:9724028pubmed:authorsCompleteYlld:pubmed
pubmed-article:9724028pubmed:pagination3763-71lld:pubmed
pubmed-article:9724028pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:meshHeadingpubmed-meshheading:9724028-...lld:pubmed
pubmed-article:9724028pubmed:year1998lld:pubmed
pubmed-article:9724028pubmed:articleTitleDeficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells.lld:pubmed
pubmed-article:9724028pubmed:affiliationUnité Interactions entre Systèmes Protéiques et Différenciation dans la Cellule Tumorale, UPRES-A CNRS 6032, Université d'Aix-Marseille I, Faculté de Pharmacie, France.lld:pubmed
pubmed-article:9724028pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9724028pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9724028lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9724028lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9724028lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9724028lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9724028lld:pubmed